Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Shanghai, Shanghai Municipality

Oncologyliquid biopsyPhase IIIListed · 688266.SH

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

What changed

Phase II trial registered: PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

2mo agoTrial registeredMay 13, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE3 registered
Dec 12, 2025
Small-cell Lung Cancer · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
ClinicalTrials.gov · NCT07189455 (opens the source filing in a new tab)
Trial
NA registered
Dec 1, 2025
Pulmonary Nodule Cm · NOT_YET_RECRUITING · sponsor: Qianfoshan Hospital · Sedation of Remazolam Combined With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery
ClinicalTrials.gov · NCT06810843 (opens the source filing in a new tab)
Trial
PHASE2 registered
Sep 15, 2025
Brugada Syndrome (BrS) · NOT_YET_RECRUITING · sponsor: National Taiwan University Hospital · Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
ClinicalTrials.gov · NCT07146880 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jul 2, 2025
Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma · RECRUITING · sponsor: Memorial Sloan Kettering Cancer Center · A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
ClinicalTrials.gov · NCT07063212 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
May 23, 2025
Non-small Cell Lung Cancer · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov · NCT06903377 (opens the source filing in a new tab)
Grant
P01 · $273k · non-dilutive
Apr 1, 2025
UNIVERSITY OF CALIFORNIA-IRVINE · PI WU, JIE · NCI · award ends Mar 31, 2030 · Single Cell Analysis Core
NIH RePORTER · NIH RePORTER 11016821 (opens the source filing in a new tab)
Grant
R01 · $579k · non-dilutive
Mar 1, 2025
UT SOUTHWESTERN MEDICAL CENTER · PI WU, JIANG · NINDS · award ends Dec 31, 2029 · Chromatin regulation of neuronal activity-induced enhancer priming and epigenetic memory
NIH RePORTER · NIH RePORTER 11072249 (opens the source filing in a new tab)
Grant
K01 · $154k · non-dilutive
Feb 8, 2025
UNIVERSITY OF ARIZONA · PI WU, JING O. · NIDDK · award ends Nov 30, 2025 · Novel Mechanisms Regulating Renal Perfusion and Kidney Redox Biology: Role in Salt Sensitive Hypertension
NIH RePORTER · NIH RePORTER 11280843 (opens the source filing in a new tab)
Grant
R01 · $510k · non-dilutive
Aug 1, 2024
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · NIBIB · award ends Apr 30, 2028 · Engineering recombinase circuits for cellular diagnostic devices
NIH RePORTER · NIH RePORTER 11140509 (opens the source filing in a new tab)
Grant
R01 · $602k · non-dilutive
Jul 16, 2024
STANFORD UNIVERSITY · PI MERCOLA, MARK · NHLBI · award ends Apr 30, 2028 · Evaluation of the AMPK-BACH1-NRF2 Axis as a Therapeutic Target for Inherited DCM
NIH RePORTER · NIH RePORTER 11138625 (opens the source filing in a new tab)
Grant
R21 · $239k · non-dilutive
Jun 1, 2024
GEORGIA STATE UNIVERSITY · PI WU, JIANHUA · NICHD · award ends May 31, 2027 · Role of congenital heart defects in motor skills and language acquisition of infants with Down syndrome
NIH RePORTER · NIH RePORTER 11095838 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Jan 31, 2024
Glioma, Medulloblastoma, Ependymoma, Glioblastoma · RECRUITING · sponsor: National Cancer Institute (NCI) · PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
ClinicalTrials.gov · NCT06161519 (opens the source filing in a new tab)
Grant
R01 · $665k · non-dilutive
Jul 1, 2023
UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VOKES, NATALIE · NCI · award ends Jun 30, 2028 · Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer
NIH RePORTER · NIH RePORTER 11093994 (opens the source filing in a new tab)
Grant
R01 · $572k · non-dilutive
Jul 1, 2023
STANFORD UNIVERSITY · PI MERCOLA, MARK · NHLBI · award ends Jun 30, 2027 · hiPSC Modeling of Restrictive Cardiomyopathy for Drug Testing
NIH RePORTER · NIH RePORTER 11137666 (opens the source filing in a new tab)
Grant
R01 · $748k · non-dilutive
Sep 15, 2022
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI REIJONEN, HELENA KRISTIINA · NIDDK · award ends Apr 30, 2027 · Extracellular Vesicle-mediated islet immune cross talk in Type 1 Diabetes pathogenesis
NIH RePORTER · NIH RePORTER 11085058 (opens the source filing in a new tab)
Grant
R01 · $764k · non-dilutive
May 15, 2022
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · NIDDK · award ends Apr 30, 2027 · Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands
NIH RePORTER · NIH RePORTER 11087669 (opens the source filing in a new tab)
Grant
R01 · $603k · non-dilutive
May 9, 2022
STANFORD UNIVERSITY · PI WU, JOSEPH C. · NHLBI · award ends Apr 30, 2027 · Elucidating ECM Signaling in Cardiac Organoids with Machine Learning and Single-cell Multiomics
NIH RePORTER · NIH RePORTER 11074091 (opens the source filing in a new tab)
Trial
NA registered
Mar 1, 2022
Patient Satisfaction, Sports Injury, Surgery, Orthopedic Disorder · COMPLETED · sponsor: Jonathan Wu · Virtual Phone Visits Compared to In-Person Physical Visits for Post-Operative Follow-Up at a Sports Medicine Clinic
ClinicalTrials.gov · NCT05998148 (opens the source filing in a new tab)
Grant
R01 · $341k · non-dilutive
Jul 22, 2021
UT SOUTHWESTERN MEDICAL CENTER · PI WU, JUN · NIGMS · award ends May 31, 2026 · Dissect formative pluripotency using cultured pluripotent stem cells
NIH RePORTER · NIH RePORTER 11087475 (opens the source filing in a new tab)
Trial
NA registered
Jun 4, 2020
Premature Ventricular Complexes · RECRUITING · sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences · TAES for FPVCs: a Pragmatic, Randomized Controlled Trial
ClinicalTrials.gov · NCT04415203 (opens the source filing in a new tab)
Trial
Study registered
Feb 21, 2020
Thyroid Gland Carcinoma, Thyroid Gland Nodule · RECRUITING · sponsor: Jonsson Comprehensive Cancer Center · Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
ClinicalTrials.gov · NCT04742608 (opens the source filing in a new tab)
Grant
R01 · $600k · non-dilutive
May 1, 2019
STANFORD UNIVERSITY · PI WU, JOSEPH C. · NHLBI · award ends Apr 30, 2027 · Single-cell Multi-omic Profiling of Drug Responses Using Pooled iPSC-CM Differentiation
NIH RePORTER · NIH RePORTER 11138577 (opens the source filing in a new tab)
Grant
R01 · $679k · non-dilutive
Apr 1, 2019
STANFORD UNIVERSITY · PI WU, JOSEPH C. · NHLBI · award ends Apr 30, 2027 · Human iPSC Model to Elucidate Metabolic Interplay in Diabetic Cardimyopathy
NIH RePORTER · NIH RePORTER 11077369 (opens the source filing in a new tab)
Grant
R01 · $657k · non-dilutive
Aug 1, 2018
STANFORD UNIVERSITY · PI WU, JOSEPH C. · NHLBI · award ends Jun 30, 2027 · Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs
NIH RePORTER · NIH RePORTER 11093580 (opens the source filing in a new tab)
Grant
R35 · $487k · non-dilutive
Sep 1, 2016
BOSTON CHILDREN'S HOSPITAL · PI WONG, WESLEY PHILIP · NIGMS · award ends May 31, 2026 · Mechanical forces in nanoscale biology: From hemostasis to single-molecule centrifugation
NIH RePORTER · NIH RePORTER 11093423 (opens the source filing in a new tab)
Grant
R01 · $322k · non-dilutive
Aug 1, 2016
OHIO STATE UNIVERSITY · PI WU, JIAN-QIU · NIGMS · award ends May 31, 2027 · Molecular Mechanisms of Cytokinesis
NIH RePORTER · NIH RePORTER 11089413 (opens the source filing in a new tab)
Grant
R01 · $767k · non-dilutive
Dec 16, 2015
STANFORD UNIVERSITY · PI WU, JOSEPH C. · NHLBI · award ends May 31, 2028 · Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCs
NIH RePORTER · NIH RePORTER 11083773 (opens the source filing in a new tab)
Grant
R01 · $675k · non-dilutive
May 1, 2012
STANFORD UNIVERSITY · PI WU, JOSEPH C. · NHLBI · award ends Mar 31, 2027 · Human Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling
NIH RePORTER · NIH RePORTER 11092199 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 1.00{"reasons":["name similarity 100%","shared principal investigator / founder","same city","same therapeutic area"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator WU, JIE is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator WU, JIANG is named on this company's filings"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator WONG, WILSON is named on this company's filings"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the trial record at 0.38{"reasons":["same city","same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
4mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
4mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Virtual Phone Visits Compared to In-Person Physical Visits for Post-Operative Follow-Up at a Sports Medicine Clinic
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Virtual Phone Visits Compared to In-Person Physical Visits for Post-Operative Follow-Up at a Sports Medicine Clinic
7mo agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
10mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Sedation of Remazolam Combined With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery
11mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: TAES for FPVCs: a Pragmatic, Randomized Controlled Trial
12mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: TAES for FPVCs: a Pragmatic, Randomized Controlled Trial
12mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Human iPSC Model to Elucidate Metabolic Interplay in Diabetic Cardimyopathy
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · hiPSC Modeling of Restrictive Cardiomyopathy for Drug Testing
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.5M · Mechanical forces in nanoscale biology: From hemostasis to single-molecule centrifugation
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCs
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Extracellular Vesicle-mediated islet immune cross talk in Type 1 Diabetes pathogenesis
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Evaluation of the AMPK-BACH1-NRF2 Axis as a Therapeutic Target for Inherited DCM
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Single-cell Multi-omic Profiling of Drug Responses Using Pooled iPSC-CM Differentiation
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Dissect formative pluripotency using cultured pluripotent stem cells
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Role of congenital heart defects in motor skills and language acquisition of infants with Down syndrome
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Molecular Mechanisms of Cytokinesis
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Human Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH K01 · $0.2M · Novel Mechanisms Regulating Renal Perfusion and Kidney Redox Biology: Role in Salt Sensitive Hypertension
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Elucidating ECM Signaling in Cardiac Organoids with Machine Learning and Single-cell Multiomics
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Engineering recombinase circuits for cellular diagnostic devices
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH P01 · $0.3M · Single Cell Analysis Core
Mar 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Chromatin regulation of neuronal activity-induced enhancer priming and epigenetic memory
Feb 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE3 registered

NA registered

PHASE2 registered

PHASE2 registered

PHASE1/PHASE2 registered

P01 · $273k · non-dilutive

R01 · $579k · non-dilutive

K01 · $154k · non-dilutive

R01 · $510k · non-dilutive

R01 · $602k · non-dilutive

R21 · $239k · non-dilutive

PHASE1/PHASE2 registered

R01 · $665k · non-dilutive

R01 · $572k · non-dilutive

R01 · $748k · non-dilutive

R01 · $764k · non-dilutive

R01 · $603k · non-dilutive

NA registered

R01 · $341k · non-dilutive

NA registered

Study registered

R01 · $600k · non-dilutive

R01 · $679k · non-dilutive

R01 · $657k · non-dilutive

R35 · $487k · non-dilutive

R01 · $322k · non-dilutive

R01 · $767k · non-dilutive

R01 · $675k · non-dilutive